Imatinib dose escalation versus sunitinib as a second-line treatment against advanced gastrointestinal stromal tumors: A nationwide population-based cohort study

BACKGROUND: Although treatment with imatinib in advanced gastrointestinal stromal tumor (GIST) patients has led to significant clinical benefits, the disease will eventually progress due to imatinib resistance. Treatment options after failure of first-line imatinib include imatinib dose escalation o...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Jun-Te, Le, Puo-Hsien, Kuo, Chang-Fu, Chiou, Meng-Jiun, Kuo, Chia-Jung, Chen, Tsung-Hsing, Lin, Chun-Jung, Chen, Jen-Shi, Yu, Huang-Pin, Yeh, Chun-Nan, Jan, Yi-Yin, Yeh, Ta-Sen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642623/
https://www.ncbi.nlm.nih.gov/pubmed/29050348
http://dx.doi.org/10.18632/oncotarget.16795

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642623/
https://www.ncbi.nlm.nih.gov/pubmed/29050348
http://dx.doi.org/10.18632/oncotarget.16795

Ejemplares similares